Myopathy with anti-HMGCR antibodies Perimysium and myofiber pathology

Neurology: Neuroimmunology and NeuroInflammation

Volumn 2, Issue 4, 2015, Pages

  Alshehri, Ali ^a   Choksi, Rati ^a   Bucelli, Robert ^a   Pestronk, Alan ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATINE KINASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; BLOOD VESSEL; CLINICAL ARTICLE; CLINICAL FEATURE; CONNECTIVE TISSUE; CREATINE KINASE BLOOD LEVEL; DISEASE ASSOCIATION; DYSPHAGIA; FEMALE; HUMAN; HUMAN TISSUE; INTERSTITIAL LUNG DISEASE; MALE; MEDICAL RECORD REVIEW; MIDDLE AGED; MUSCLE CELL; MUSCLE NECROSIS; MUSCLE REGENERATION; MYOPATHY; ONSET AGE; PERIMYSIUM; PRIORITY JOURNAL; RASH; RETROSPECTIVE STUDY; REVIEW; WEAKNESS;

EID: 84977747319     PISSN: None     EISSN: 23327812     Source Type: Journal    
DOI: 10.1212/NXI.0000000000000124     Document Type: Review

References (22)

1. Hoogendijk J, Amato A, Lecky B., et al. 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands. Neuromuscul Disord 2004; 14:337-345.
2. Gunawardena H, Betteridge ZE, McHugh NJ Myositis-specific autoantibodies: their clinical and pathogenic significance in disease expression. Rheumatology (Oxford) 2009; 48:607-612.
3. Pestronk A. Acquired immune and inflammatory myopathies: pathologic classification. Curr Opin Rheumatol 2011; 23:595-604.
4. Christopher-Stine L., Casciola-Rosen LA, Hong G., Chung T, Corse AM, Mammen AL A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy. Arthritis Rheum 2010; 62:2757-2766.
5. Mammen AL, Chung T, Christopher-Stine L, et al. Autoantibodies against 3-hydroxy-3-methylglutarylcoenzyme a reductase (HMGCR) in patients with statin-associated autoimmune myopathy. Arthritis Rheum 2011; 63: 713-721.
6. Allenbach Y, Drouot L, Rigolet A., et al. Anti-HMGCR autoantibodies in European patients with autoimmune necrotizing myopathies: inconstant exposure to statin. Medicine (Baltimore) 2014; 93:150-157.
7. Albayda J, Mammen AL. Is statin-induced myositis part of the polymyositis disease spectrum? Curr Rheumatol Rep 2014; 16:433.
8. Hamann PD, Cooper RG, McHugh N.J., Chinoy H. Statin-induced necrotizing myositis - a discrete autoimmune entity within the "statin-induced myopathy spectrum". Autoimmun Rev 2013; 12:1177-1181.
9. Limaye V, Bundell C, Hollingsworth P., et al. Clinical and genetic associations of autoantibodies to 3-hydroxy-3-methyl-glutaryl-coenzyme a reductase in patients with immune-mediated myositis and necrotizing myopathy. Muscle Nerve Epub 2014 Dec 18.
10. Watanabe Y, Suzuki S, Nishimura H., et al. Statins and myotoxic effects associated with anti-3-hydroxy-3-methylglutaryl-coenzyme a reductase autoantibodies: an observational study in Japan. Medicine (Baltimore) 2015; 94:e416.
11. Rose MR; ENMC IBM Working Group. 188th ENMC International Workshop: Inclusion Body Myositis, 2-4 December 2011, Naarden, The Netherlands. Neuromuscul Disord 2013; 23:1044-1055.
12. Mozaffar T, Pestronk A. Myopathy with anti-Jo-1 antibodies: pathology in perimysium and neighbouring muscle fibres. J Neurol Neurosurg Psychiatry 2000; 68:472-478.
13. Miller T, Al-Lozi MT, Lopate G., Pestronk A. Myopathy with antibodies to the signal recognition particle: clinical and pathological features. J Neurol Neurosurg Psychiatry 2002; 73:420-428.
14. Mammen AL, Pak K, Williams E.K., et al. Rarity of anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies in statin users, including those with self-limited musculoskeletal side effects. Arthritis Care Res (Hoboken) 2012; 64: 269-272.
15. Mohassel P, Mammen AL The spectrum of statin myopathy. Curr Opin Rheumatol 2013; 25:747-752.
16. Drouot L, Allenbach Y, Jouen F., et al. Exploring necrotizing autoimmune myopathies with a novel immunoassay for anti-3-hydroxy-3-methyl-glutaryl-CoA reductase autoantibodies. Arthritis Res Ther 2014; 16:R39.
17. Stenzel W, Preuße C, Allenbach Y., et al. Nuclear actin aggregation is a hallmark of anti-synthetase syndromeinduced dysimmune myopathy. Neurology 2015; 84: 1346-1354.
18. Allenbach Y, Benveniste O. Acquired necrotizing myopathies. Curr Opin Neurol 2013; 26:554-560.
19. Cai C, Alshehri A, Choksi R., Pestronk A. Regional ischemic immune myopathy: a paraneoplastic dermatomyopathy. J Neuropathol Exp Neurol 2014; 73:1126-1133.
20. Koffman BM, Rugiero M, Dalakas MC Immune-mediated conditions and antibodies associated with sporadic inclusion body myositis. Muscle Nerve 1998; 21:115-117.
21. Dalakas MC, Illa I, Gallardo E., Juarez C. Inclusion body myositis and paraproteinemia: incidence and immunopathologic correlations. Ann Neurol 1997; 41: 100-104.
22. Werner JL, Christopher-Stine L, Ghazarian S.R., et al. Antibody levels correlate with creatine kinase levels and strength in anti-HMG-CoA reductase-associated autoimmune myopathy. Arthritis Rheum 2012; 64: 4087-4093.